NCT06319118View on ClinicalTrials.gov

A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.

NAActive, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 30, 2024

Conditions
Salivation in Parkinson's Disease
Interventions
DRUG

Placebo

placebo + usual care, placebo 5 mg daily; 2.5mg 2 times daily, after breakfast and dinner.

DRUG

dihydroergotine mesylate sustained-release tablets

Dihydroergotine mesylate extended-release tablets + conventional treatment, dihydroergotine mesylate sustained-release tablets 5mg daily; 2.5mg 2 times daily, after breakfast and dinner.

Trial Locations (1)

215004

The Second Arilliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Soochow University

OTHER

NCT06319118 - A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease. | Biotech Hunter | Biotech Hunter